Tetra Technologies Inc. (TTI)
Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis Transcript
Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis Transcript
Tetra Technologies Q2 Earnings Call Highlights
Tetra Technologies NYSE: TTI reported second-quarter revenue of $185.7 million, up 19% sequentially and 7% from the prior-year period, as strength in international and offshore operations offset delayed Middle East fluid shipments tied to regional conflict.
Tetra Technologies (TTI) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Tetra Technologies (TTI) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
TETRA Technologies, Inc. (TTI) Q2 2026 Earnings Call Transcript
TETRA Technologies, Inc. (TTI) Q2 2026 Earnings Call Transcript
Tetra Technologies (TTI) Q2 Earnings Meet Estimates
Tetra Technologies (TTI) came out with quarterly earnings of $0.08 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.09 per share a year ago.
Compared to Estimates, Tetra Technologies (TTI) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Tetra Technologies (TTI) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Tetra Technologies (TTI) to Report Q2 Results: What to Know Ahead of the Release
Tetra Technologies (TTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript
Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript
Tetra Technologies (TTI) Soars 6.6%: Is Further Upside Left in the Stock?
Tetra Technologies (TTI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
TETRA Technologies, Inc. (TTI) Presents at J.P. Morgan Natural Resources Conference 2026 Transcript
TETRA Technologies, Inc. (TTI) Presents at J.P. Morgan Natural Resources Conference 2026 Transcript
Can Viavi's New TETRA Testing Upgrade Strengthen Its Growth Story?
VIAV's new TETRA testing upgrade for the CX300 aims to speed deployments, cut costs, and reinforce its position in mission-critical radio testing.
TETRA Technologies: Deep In The Oil Patch, A Critical Minerals Play Is Taking Shape
TETRA Technologies reported decade-high Q1 2026 revenue and EBITDA, with EPS coming 100% above estimates despite flat year-over-year growth. The company is constructing an Arkansas bromine facility for zinc bromide electrolyte battery supply. This is the project that contributes to the growth of the company in the near future. At 14x EV/EBITDA, TTI trades at the same multiple as Generac, although TTI holds bromine supply chain exposure and dominant deepwater completion fluid market share.
